Clinical trial / 2025
Accounting for background diet and adherence via biomarkers revealed larger effect sizes for cocoa flavanol intervention outcomes in COSMOS.
Using validated flavanol biomarkers, researchers assessed background diet and adherence in a subcohort of the randomized COcoa Supplement and Multivitamin Outcomes Study. They found 20% of participants had a flavanol background intake as high as the intervention, and about 33% in the intervention arm did not reach expected biomarker levels. Compared with intention-to-treat and per-protocol analyses, biomarker-based analysis showed larger effect sizes: total CVD events HR 0.65 (95% CI: 0.47, 0.89), CVD mortality HR 0.44 (0.20, 0.97), all-cause mortality HR 0.54 (0.37, 0.80), and major CVD events HR 0.48 (0.31, 0.74).
- Study type
- Randomized controlled trial subcohort analysis
- Who was studied
- Subcohort of participants in the COSMOS trial
- What was measured
- Total cardiovascular disease events, CVD mortality, all-cause mortality, major CVD events
THE PAPER
The overlooked impact of background diet and adherence in nutrition trials.
Ottaviani JI, Schroeter H, Bier DM, Erdman JW, Sesso HD, Manson JE, Kuhnle GGC. Food Funct, 2025.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.